论文部分内容阅读
目的探讨喜炎平联合阿糖腺苷治疗小儿病毒性脑炎的临床疗效及其对T细胞亚群的影响。方法随机选取我院儿科门诊于2014年3月—2016年3月收治的94例小儿病毒性脑炎患者进行研究,随机分为对照组(47例,单纯经阿糖腺苷治疗)和观察组(47例,经喜炎平+阿糖腺苷联合治疗),对比两组患儿的临床疗效、症状消失时间、预后和治疗前后的T细胞亚群变化。结果观察组的总有效率为91.49%,明显高于对照组的76.60%(P<0.05);并发症发生率、病死率以及后遗症发生率均明显低于对照组,且痊愈率高于对照组(均P<0.05)。观察组的退热时间、头痛消失时间以及意识清醒时间等临床症状改善时间均明显短于对照组,治疗后,两组患儿的各T细胞亚群数量均明显提高,且观察组显著高于对照组,差异有统计学意义(P<0.05)。结论采用喜炎平与阿糖腺苷联合治疗小儿病毒性脑炎具有显著的临床疗效,可迅速改善临床症状,促进预后,并有助于提高患儿T细胞亚群的水平。
Objective To investigate the clinical efficacy of Xiyanping combined with vidarabine in the treatment of pediatric viral encephalitis and its effect on T cell subsets. Methods A total of 94 cases of pediatric viral encephalitis in our pediatric outpatient department from March 2014 to March 2016 were randomly selected and divided into control group (n = 47, treated with vidarabine alone) and observation group (47 cases treated with Xiyanping + Vidarabine). The clinical efficacy, symptom disappearance time, prognosis and changes of T cell subsets before and after treatment were compared between the two groups. Results The total effective rate in the observation group was 91.49%, which was significantly higher than that in the control group (76.60%, P <0.05). Complications, mortality and sequelae were significantly lower than those in the control group (All P <0.05). The observation group’s antipyretic time, headache disappear time and conscious time of consciousness and other clinical symptoms were significantly shorter than the control group, after treatment, the two groups of children’s T cell subsets were significantly increased, and the observation group was significantly higher than Control group, the difference was statistically significant (P <0.05). Conclusion The combination of Xiyanping and Vidarabine in the treatment of children with viral encephalitis has significant clinical efficacy, can rapidly improve clinical symptoms, promote prognosis, and help to improve the level of T-cell subsets in children.